VMD-102 Drug Study for Advanced Cancers
Part of Cancer, Digestive system, Eyes & vision, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This study tests a new drug called VMD-102 in patients with advanced liver cancer, melanoma, kidney cancer, lung cancer, or colon cancer that hasn't responded to standard treatments. The trial will help determine if VMD-102 is safe and effective at slowing or stopping cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (unresectable or spread) liver, melanoma, kidney, lung, or colon cancer that hasn't worked with standard treatments, or you can't tolerate them
- Your overall health and ability to care for yourself is good (ECOG score 0 or 1)
- You have at least one measurable tumor that can be tracked on imaging, and if you've had radiation or other local therapy before, the tumor must have grown by at least 25% since that treatment
- Your blood counts, liver function, and kidney function are adequate based on recent lab work
- You can swallow and take oral medication in tablet form
- You've completed all prior cancer treatments at least 4 weeks before starting this study, and any side effects from prior treatment have resolved
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
This trial tests an experimental drug called VVD-133214, alone or with other medicines, in people with advanced solid tumors that have specific DNA repair problems (MSI-H/dMMR). The goal is to see if it is safe and effective.
This trial tests a new drug called VBC101 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if VBC101 is safe and effective.
This trial tests a new drug, VBC103, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink or slow the growth of these tumors.
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
This Phase 1 trial tests VVD-130037, a new experimental medicine, to see if it is safe and tolerable in people with advanced (metastatic or unresectable) solid cancers. If you have already tried standard treatments and your body can handle study medication, you may be eligible—especially for certain lung, head and neck, or esophageal cancer types with specific genetic changes.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.